Cargando…

Recent advances in the development of RIPK2 modulators for the treatment of inflammatory diseases

Receptor-interacting serine/threonine kinase 2 (RIPK2) is a vital immunomodulator that plays critical roles in nucleotide-binding oligomerization domain 1 (NOD1), NOD2, and Toll-like receptors (TLRs) signaling. Stimulated NOD1 and NOD2 interact with RIPK2 and lead to the activation of nuclear factor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pham, Anh-Tuan, Ghilardi, Amanda Franceschini, Sun, Lijun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028200/ https://www.ncbi.nlm.nih.gov/pubmed/36959850 http://dx.doi.org/10.3389/fphar.2023.1127722

Ejemplares similares

Advances in RIPK1 kinase inhibitors
por: Chen, Lu, et al.
Publicado: (2022)

Erratum: Advances in RIPK1 kinase inhibitors
Publicado: (2023)

RIPK2 as a New Therapeutic Target in Inflammatory Bowel Diseases
por: Honjo, Hajime, et al.
Publicado: (2021)

RIPK2: a promising target for cancer treatment
por: You, Jieqiong, et al.
Publicado: (2023)

RIPK1 in the inflammatory response and sepsis: Recent advances, drug discovery and beyond
por: Liu, Xiaoyu, et al.
Publicado: (2023)

Recent Developments About the Pathogenesis of Dry Eye Disease: Based on Immune Inflammatory Mechanisms
por: Yu, Lifei, et al.
Publicado: (2021)

Editorial: Recent advances in novel therapeutic molecules and targets for inflammatory diseases
por: Li, Feng, et al.
Publicado: (2023)

Corrigendum: RIPK1 in the inflammatory response and sepsis: recent advances, drug discovery and beyond
por: Liu, Xiaoyu, et al.
Publicado: (2023)

Thiopurines: Recent Topics and Their Role in the Treatment of Inflammatory Bowel Diseases
por: Tominaga, Keiichi, et al.
Publicado: (2021)

Yi-Qi-Jian-Pi Formula Suppresses RIPK1/RIPK3-Complex-Dependent Necroptosis of Hepatocytes Through ROS Signaling and Attenuates Liver Injury in Vivo and in Vitro
por: Wang, Feixia, et al.
Publicado: (2021)

Antidepressant Mechanism of Traditional Chinese Medicine Formula Xiaoyaosan in CUMS-Induced Depressed Mouse Model via RIPK1-RIPK3-MLKL Mediated Necroptosis Based on Network Pharmacology Analysis
por: Yan, Zhi-Yi, et al.
Publicado: (2021)

Fluorofenidone Alleviates Renal Fibrosis by Inhibiting Necroptosis Through RIPK3/MLKL Pathway
por: Dai, Qin, et al.
Publicado: (2020)

Recent Advances in Chitosan and its Derivatives in Cancer Treatment
por: Ding, Jingxian, et al.
Publicado: (2022)

Recent advances in JAK inhibitors for the treatment of metabolic syndrome
por: Collotta, Debora, et al.
Publicado: (2023)

Induction of RIPK3/MLKL-mediated necroptosis by Erigeron breviscapus injection exhibits potent antitumor effect
por: Guo, Xiuping, et al.
Publicado: (2023)

Recent Advances in Traditional Chinese Medicine for Treatment of Podocyte Injury
por: Yao, Tianwen, et al.
Publicado: (2022)

Update on the recent development of allosteric modulators for adenosine receptors and their therapeutic applications
por: Pasquini, Silvia, et al.
Publicado: (2022)

RIPK2: New Elements in Modulating Inflammatory Breast Cancer Pathogenesis
por: Zare, Alaa, et al.
Publicado: (2018)

A Putative Serine Protease is Required to Initiate the RIPK3-MLKL—Mediated Necroptotic Death Pathway in Neutrophils
por: Wang, Xiaoliang, et al.
Publicado: (2021)

Low-Dose Resveratrol Inhibits RIPK3-Mediated Necroptosis and Delays the Onset of Age-Related Hearing Loss
por: Yang, Zeyin, et al.
Publicado: (2022)

Corrigendum: Induction of RIPK3/MLKL-mediated necroptosis by Erigeron breviscapus injection exhibits potent antitumor effect
por: Guo, Xiuping, et al.
Publicado: (2023)

Glioblastoma Treatments: An Account of Recent Industrial Developments
por: Alphandéry, Edouard
Publicado: (2018)

The Role of RIPK1 and RIPK3 in Cardiovascular Disease
por: DeRoo, Elise, et al.
Publicado: (2020)

Recent advances in peptide-based therapeutic strategies for breast cancer treatment
por: Li, Ling, et al.
Publicado: (2023)

Recent advances of exosomes in age-related macular degeneration
por: Gu, Feng, et al.
Publicado: (2023)

Recent evaluation about inflammatory mechanisms in nonalcoholic fatty liver disease
por: Song, Chong, et al.
Publicado: (2023)

Recent advances in voltage-gated sodium channels, their pharmacology, and related diseases
por: Desaphy, Jean-François, et al.
Publicado: (2013)

Research advances in treatment methods and drug development for rare diseases
por: Han, Qiaoqiao, et al.
Publicado: (2022)

Cpd-42 protects against calcium oxalate nephrocalcinosis-induced renal injury and inflammation by targeting RIPK3-mediated necroptosis
por: Hou, Bingbing, et al.
Publicado: (2022)

Editorial: Recent Advances in Cardiotoxicity Testing
por: Mohamed, Tamer M. A., et al.
Publicado: (2021)

Nanosystems for chemodynamic based combination therapy: Strategies and recent advances
por: Li, Minghui, et al.
Publicado: (2022)

Editorial: Recent Advances in Voltage-Gated Sodium Channels, their Pharmacology and Related Diseases
por: Chahine, Mohamed, et al.
Publicado: (2016)

Recent advances on development of p21-activated kinase 4 inhibitors as anti-tumor agents
por: Li, Yang, et al.
Publicado: (2022)

Herbal Therapy for the Treatment of Acetaminophen-Associated Liver Injury: Recent Advances and Future Perspectives
por: Chang, Ling, et al.
Publicado: (2020)

Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment
por: Wu, Xianbo, et al.
Publicado: (2022)

Recent advances in circadian rhythms in cardiovascular system
por: Chen, Lihong, et al.
Publicado: (2015)

Recent Advances in Nano-Therapeutic Strategies for Osteoarthritis
por: Guo, Xinjing, et al.
Publicado: (2022)

Editorial: Recent advances in radiation medical countermeasures
por: Tichy, Ales, et al.
Publicado: (2022)

Targeting RIPK1 kinase for modulating inflammation in human diseases
por: Li, Wanjin, et al.
Publicado: (2023)

Targeting RIPK1 for the treatment of human diseases
por: Degterev, Alexei, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jdhg21jk61hhi3kq2e4otll7qn